Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting

Catherine M Claussen, MS, Hans Lee, MD, Jatin J. Shah, MD, Tiffany Richards, ANP, Nina Shah, MD, Krina Patel, MD, Qaiser Bashir, MD, Simrit Parmar, MD, Sheeba Thomas, MD, Yago Nieto, MD PhD, Muzaffar H. Qazilbash, MD, Richard Eric Davis, MD, Sattva S. Neelapu, MD, Donna M. Weber, MD, Robert Z. Orlowski, PhD, MD, Lei Feng, MS, Elisabet E. Manasanch, MD

Blood (2016) 128 (22): 5628.

https://doi.org/10.1182/blood.V128.22.5628.5628

Published: 2016

Journal Articles

A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson

Ghulam Rehman Mohyuddin, MD, Muhammad Salman Faisal, MBBS, Nina Shah, MD, Qaiser Bashir, MD, Chitra Hosing, MD, Krina Patel, MD, Uday R. Popat, MD, Simrit Parmar, MD, Gabriela Rondon, MD, Ruby Delgado, Donna M. Weber, MD, Jatin J. Shah, MD, Sheeba Thomas, MD, Elisabeth E. Manasanch, MD, Robert Z. Orlowski, PhD, MD, Richard E. Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2016) 128 (22): 4613.

https://doi.org/10.1182/blood.V128.22.4613.4613

Published: 2016

Journal Articles

Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting

Catherine M Claussen, MS, Tammy Chuang, Jatin Shah, MD, Hans Lee, MD, Nina Shah, MD, Krina K Patel, Qaiser Bashir, MD, Simrit Parmar, MD, Sheeba Thomas, MD, Muzaffar Qazilbash, MD, Richard Eric Davis, MD, Sattva S. Neelapu, MD, Donna Weber, MD, Robert Z. Orlowski, PhD, MD, Lei Feng, MS, Elisabet E. Manasanch, MD

Blood (2015) 126 (23): 5390.

https://doi.org/10.1182/blood.V126.23.5390.5390

Published: 2015

Journal Articles

Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia

Steven P Treon, MD, PhD, Christina K Tripsas, Leukothea Ioakimidis, Diane Warren, Christopher Patterson, Leonard Heffner, MD, Herbert Eradat, MD, MS, Stephanie A. Gregory, MD, Sheeba Thomas, MD, Ranjana Advani, MD, Rachid Baz, Ashraf Z. Badros, MD, Jeffrey Matous, MD, Kenneth C. Anderson, MD, Irene M. Ghobrial, MD

Blood (2011) 118 (21): 2951.

https://doi.org/10.1182/blood.V118.21.2951.2951

Published: 2011

Journal Articles

Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma

Jatin J Shah, MD, Robert Z. Orlowski, MD, PhD, Raymond Alexanian, MD, Michael Wang, MD, Sheeba Thomas, MD, Muzaffar H. Qazilbash, MD, Simrit Parmar, M.D., Nina Shah, MD, Qaiser Bashir, MD, Uday Popat, MD, Donna Weber, MD

Blood (2010) 116 (21): 1948.

https://doi.org/10.1182/blood.V116.21.1948.1948

Published: 2010

Journal Articles

A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma

Jatin J Shah, MD, Jeffrey A. Zonder, MD, Adam Cohen, Donna Weber, MD, Sheeba Thomas, MD, Michael Wang, MD, Jonathan L. Kaufman, MD, Steven Michael Burt, Duncan Walker, Burgess Freeman, Selena Armistead Rush, BS, Ann Ptaszynski, Robert Z. Orlowski, MD, PhD, Sagar Lonial, MD

Blood (2010) 116 (21): 1959.

https://doi.org/10.1182/blood.V116.21.1959.1959

Published: 2010

Journal Articles

Curability of Multiple Myeloma.

Kay B Delasalle, BS, Luhua Wang, MD, Donna Weber, MD, Sergio A. Giralt, MD, Sheeba Thomas, MD, Jatin Shah, MD, Beverly Handy, MD, Robert Z. Orlowski, MD, PhD, Raymond Alexanian, M.D.

Blood (2009) 114 (22): 3864.

https://doi.org/10.1182/blood.V114.22.3864.3864

Published: 2009

Journal Articles

Survival Disparities Between African-American and Caucasian Patients with Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation.

Nina Shah, MD, Donna M Weber, M.D., Michael Wang, MD, Sheeba Thomas, MD, Jatin Shah, MD, Sergio Giralt, MD, Raymond Alexanian, M.D., Robert Z Orlowski, M.D., Ph.D., Muzaffar H. Qazilbash, MD, Tiffany Avery, M.D., MPH

Blood (2009) 114 (22): 1395.

https://doi.org/10.1182/blood.V114.22.1395.1395

Published: 2009

Journal Articles

Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma

Suzanne M. Cole, MD, Rima Saliba, Matteo Pelosini, M.D., Floralyn L Mendoza, Donna Weber, MD, Michael Wang, MD, Sheeba Thomas, MD, Robert Z. Orlowski, MD, PhD, Jatin Shah, MD, Amin Alousi, MD, Chitra Hosing, MD, Uday Popat, MD, Partow Kebriaei, MD, Paolo Anderlini, MD, Issa F. Khouri, Richard Champlin, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD

Blood (2008) 112 (11): 3298.

https://doi.org/10.1182/blood.V112.11.3298.3298

Published: 2008

Journal Articles

Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD).

Sergio Giralt, MD, Rupi Thandi, MD, Muzaffar Qazilbash, MD, Floralyn Mendoza, BS, Eric Han, BS, Chitra Hosing, MD, Michael Wang, MD, Sheeba Thomas, MD, Raymond Alexanian, MD, Richard Champlin, MD, Donna Weber, MD

Blood (2007) 110 (11): 948.

https://doi.org/10.1182/blood.V110.11.948.948

Published: 2007

Journal Articles

Complete Remission Represents the Major Surrogate Marker of Long Survival in Multiple Myeloma.

Michael Wang, MD, Kay Delasalle, Sheeba Thomas, MD, Sergio Giralt, MD, Raymond Alexanian, MD

Blood (2006) 108 (11): 403.

https://doi.org/10.1182/blood.V108.11.403.403

Published: 2006

NARROW

Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting

A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson

Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting

Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia

Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma

A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma

Curability of Multiple Myeloma.

Survival Disparities Between African-American and Caucasian Patients with Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation.

Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma

Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD).

Complete Remission Represents the Major Surrogate Marker of Long Survival in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only